Navigation Links
Trial seeks to sniff out cancer

Cancer smells different. Past research has shown that dogs can detect lung cancer in a person's breath with great accuracy. But dogs are tricky to use as a diagnostic tool; what does it mean when a dog barks once compared to barking twice?

National Jewish Health and Metabolomx are working to identify exactly what dogs smell in a cancer patient's breath and how that information might be used to detect lung cancer.

"We know that early detection of lung cancer can greatly improve a patient's chances of survival," said James Jett, MD, Professor of Medicine at National Jewish Health. "The multitude of chemicals in a person's breath may provide valuable insight into what is occurring inside a person's body, and a noninvasive method to detect lung cancer before a person feels any symptoms."

Lung cancer is the number one cause of cancer deaths in the United States, killing about 160,000 Americans every year; more than breast, colon and prostate cancer deaths combined.

Early detection of lung cancer dramatically improves a patient's curative treatment options. Five-year survival for patients with advanced, stage IV disease is only 1 percent, while those whose cancer is detected early at stage I have a 70 to 80 percent of surviving five years and being cured.

Currently, five year-survival of all lung cancer in the United States is only 16 percent, because the disease is usually detected only after it becomes symptomatic and is at an advanced stage.

National Jewish Health is now enrolling participants in a trial to identify chemicals in exhaled breath that may be associated with lung cancer. Patients with lung cancer who have been diagnosed but not yet treated are eligible for the study. So are patients at high risk for developing lung cancer older than 40, and a 10-pack-year history of smoking with a parent or sibling who has been diagnosed with lung cancer. Also eligible are those older than 40 with an indeterminate lung nodule of 3-20 millimeters, and those participating in other lung-cancer screening trials.

Dr. Jett and his colleagues will use a machine developed by Metabolomx that has 128 sensors that detect volatile organic compounds in a person's breath. They will seek to detect a cancer signature in the different levels of those chemicals. Participation in the trial will take about one hour for completion of a questionnaire and exhaled breath test. The actual breath test takes 5 minutes and is painless.


Contact: William Allstetter
National Jewish Health

Related medicine news :

1. Controversial vaccine trial should never have been run in India, researchers say
2. Tai Chi increases brain size, benefits cognition in randomized controlled trial of Chinese elderly
3. Atrial fibrillation: Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment
4. Psychoeducational intervention changes patient attitudes on clinical trials participation
5. Alzheimers vaccine trial a success
6. Canada should significantly increase its funding of randomized clinical trials
7. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Trial Set to See if Drug Can Prevent Alzheimers
10. Palpitations are predictive of future atrial fibrillation
11. New Weight-Loss Drug Shows Promise in Trial
Post Your Comments:
(Date:11/30/2015)... ... ... While powdered supplements and drinks can reduce food preparation time, locating the ... has found an easy to keep track of the scoop. , He developed a ... a canister or other container handy and readily accessible. As such, it prevents the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Volpara Solutions ... density assessment and enterprise analytics solutions, here at the 101st Annual Radiological ... booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements of volumetric ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. Whether ... among us. It is your perspective, however, that determines how you view death in ... Sky understands that she may see death more frequently than most. As she was ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming Dec. ... care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel Corp. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... medicines directed at up to 10 G protein-coupled receptor ... PFE ) to research and develop potential new medicines ... targets across multiple therapeutic areas. --> Heptares ... development company and wholly-owned subsidiary of Sosei Group Corporation ...
(Date:11/30/2015)... TEL AVIV, Israel , November 30, 2015 /PRNewswire/ ... EMITF ) ("Elbit" or the "Company") announced today that it ... Ministry of Food and Drug Safety (MFDS) has approved ... behavioral disorders. --> --> ... presenting a non-invasive treatment alternative that combines two technologies: ...
Breaking Medicine Technology: